{"prompt": "['Abbreviated Title: Ph II SGI110 in Peds & Adults', '41', 'Version Date: 07/22/2019', 'Gingival pain; Hemorrhoids; Ileus; Lip pain; Lower gastrointestinal hemorrhage; Oral hemorrhage;', 'Oral pain; Periodontal disease; Rectal hemorrhage; Rectal pain; Small intestinal mucositis; Small', 'intestinal obstruction; Toothache; Typhlitis; Upper gastrointestinal hemorrhage', 'GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS - Chills; Edema', 'limbs; Gait disturbance; General disorders and administration site conditions - Other (exercise', 'tolerance decreased); General disorders and administration site conditions - Other (general physical', 'health deterioration); General disorders and administration site conditions - Other (systemic', 'inflammatory response syndrome [SIRS]); Infusion site extravasation; Localized edema; Malaise;', 'Multi-organ failure; Non-cardiac chest pain', 'HEPATOBILIARY DISORDERS - Cholecystitis', 'IMMUNE SYSTEM DISORDERS - Allergic reaction', 'INVESTIGATIONS - Activated partial thromboplastin time prolonged; Alanine aminotransferase', 'increased; Alkaline phosphatase increased; Aspartate aminotransferase increased; Blood bilirubin', 'increased; Creatinine increased; Ejection fraction decreased; Electrocardiogram QT corrected', 'interval prolonged; GGT increased; INR increased; Investigations - Other (elevated c-reactive', 'proteins [c-reactive protein increased]); Investigations - Other (klebsiella test positive);', 'Investigations - Other (reticulocyte count decreased); Investigations - Other (thrombocytosis);', 'Lymphocyte count increased; Weight loss', 'METABOLISM AND NUTRITION DISORDERS - Acidosis; Alkalosis; Dehydration;', 'Hypercalcemia; Hyperglycemia; Hyperkalemia; Hyperphosphatemia; Hyperuricemia;', 'Hypoalbuminemia; Hypocalcemia; Hypoglycemia; Hypokalemia; Hypomagnesemia; Hyponatremia;', 'Hypophosphatemia; Metabolism and nutrition disorders - Other (failure to thrive); Metabolism and', 'nutrition disorders - Other (gout)', 'MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS - Arthralgia; Arthritis;', 'Back pain; Bone pain; Flank pain; Generalized muscle weakness; Joint range of motion decreased;', 'Muscle cramp; Musculoskeletal and connective tissue disorder - Other (joint contracture);', 'Musculoskeletal and connective tissue disorder - Other (musculoskeletal stiffness); Musculoskeletal', 'and connective tissue disorder - Other (pain in jaw); Myalgia; Neck pain; Pain in extremity', 'NERVOUS SYSTEM DISORDERS - Ataxia; Dysgeusia; Lethargy; Paresthesia; Presyncope;', 'Syncope', 'PSYCHIATRIC DISORDERS - Anxiety; Delirium; Depression', 'RENAL AND URINARY DISORDERS - Acute kidney injury; Hematuria; Urinary frequency;', 'Urinary tract pain; Urinary urgency', 'REPRODUCTIVE SYSTEM AND BREAST DISORDERS - Penile pain; Vaginal hemorrhage', 'RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS - Adult respiratory distress', 'syndrome; Atelectasis; Bronchopulmonary hemorrhage; Cough; Hypoxia; Nasal congestion;', 'Oropharyngeal pain; Pleural effusion; Pleuritic pain; Pneumonitis; Respiratory failure; Respiratory,', 'thoracic and mediastinal disorders - Other (oropharyngeal blistering); Rhinorrhea; Sneezing;', 'Wheezing', 'SKIN AND SUBCUTANEOUS TISSUE DISORDERS - Alopecia; Bullous dermatitis; Dry skin;', 'Hyperhidrosis; Lipohypertrophy; Pruritus; Rash acneiform; Skin and subcutaneous tissue disorders -']['Abbreviated Title: Ph II SGI110 in Peds & Adults', '42', 'Version Date: 07/22/2019', 'Other (dermal cyst); Skin and subcutaneous tissue disorders - Other (granuloma annulare); Skin and', 'subcutaneous tissue disorders - Other (onychoclasis); Skin induration; Skin ulceration', 'VASCULAR DISORDERS - Hematoma; Hot flashes; Hypertension; Hypotension;', 'Thromboembolic event', 'Note: SGI-110 (Guadecitabine) in combination with other agents could cause an exacerbation of any', 'adverse event currently known to be caused by the other agent, or the combination may result in', 'events never previously associated with either agent.', '9.2 ADVERSE Event CHARACTERISTICS', 'CTCAE term (AE description) and grade: The descriptions and grading scales found', 'in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version', '5.0 will be utilized for AE reporting. All appropriate treatment areas should have access', 'to a copy of the CTCAE version 5.0. A copy of the CTCAE version 5.0 can be', 'downloaded from the CTEP website', 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm.', 'For expedited reporting purposes only:', '-', 'AEs for the agent that are bold and italicized in the CAEPR (i.e., those listed in the', 'SPEER column, Section 9.1.1) should be reported through CTEP-AERS only if the', 'grade is above the grade provided in the SPEER.', '-', 'Other AEs for the protocol that do not require expedited reporting are outlined in', 'section 9.3.3.', 'Attribution of the AE:', '-', 'Definite - The AE is clearly related to the study treatment.', '-', 'Probable - The AE is likely related to the study treatment.', '-', 'Possible - The AE may be related to the study treatment.', '-', 'Unlikely - The AE is doubtfully related to the study treatment.', '-', 'Unrelated - The AE is clearly NOTrelated to the study treatment.', '9.3 EXPEDITED ADVERSE Event REPORTING TO CTEP', '9.3.1 Expedited AE reporting', 'Expedited AE reporting for this study must use CTEP-AERS (CTEP Adverse Event Reporting', 'System), accessed via the CTEP website (https://eapps-ctep.nci.nih.gov/ctepaers). The reporting', 'procedures to be followed are presented in the \"NCI Guidelines for Investigators: Adverse Event', 'Reporting Requirements for DCTD (CTEP and CIP) and DCP INDs and IDEs\" which can be', 'downloaded from the CTEP website', ' (http://ctep.cancer.gov/protocolDevelopment/electronic: applications/adverse events.htm).', 'These requirements are briefly outlined in the tables below (Section 9.3.3).', 'In the rare occurrence when Internet connectivity is lost, a 24-hour notification is to be made to', 'CTEP by telephone at 301-897-7497. Once Internet connectivity is restored, the 24-hour']\n\n###\n\n", "completion": "END"}